ACTA1 and idiopathic pulmonary fibrosis: Thus, either targeting MAP3K19 alone (with AXP2258) or in combination with pirfenidone significantly modulated myofibroblast differentiation as determined by αSMA protein and collagen 1 protein levels in cell lines derived from patients who exhibited slow progression of IPF.